

SECURITIES AND EXCHANGE COMMISSION

FORM NTN 10K

Notices of late filings of Form 10-K or 10-KSB

Filing Date: **2005-05-02** | Period of Report: **2004-12-31**  
SEC Accession No. [0000930413-05-003289](#)

([HTML Version](#) on [secdatabase.com](#))

FILER

**XENOMICS INC**

CIK: [1213037](#) | IRS No.: [043721895](#) | State of Incorporation: **FL** | Fiscal Year End: **0131**  
Type: **NTN 10K** | Act: **34** | File No.: [333-103083](#) | Film No.: [05791421](#)  
SIC: **7389** Business services, nec

Mailing Address  
420 LEXINGTON AVENUE  
SUITE 1701  
NEW YORK NY 10170

Business Address  
420 LEXINGTON AVENUE  
SUITE 1701  
NEW YORK NY 10170  
732-438-8290

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

(Check One):  Form 10-K and Form 10-KSB       Form 20-F       Form 11-K  
 Form 10-Q and Form 10-QSB       Form N-SAR

For Period Ended: December 31, 2004

Transition Report on Form 10-K       Transition Report on Form 10-Q  
 Transition Report on Form 20-F       Transition Report on Form N-SAR  
 Transition Report on Form 11-K

For the Transition Period Ended : \_\_\_\_\_

Read attached instruction sheet before preparing form. Please print or type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification related to a portion of the filing checked above, identify the item(s) to which the notification relates:

-----

PART I  
REGISTRANT INFORMATION

Full name of registrant: Xenomics, Inc.

Former name if applicable: \_\_\_\_\_

Address of principal executive office (street and number):  
420 LEXINGTON AVENUE, SUITE 1701  
-----

City, state and zip code: New York, New York 10170

PART II  
RULE 12b-25 (b) and (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)

- (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense.
- [X] (b) The subject annual report, semi-annual report, transition report on Form 10-K, 20-F, 11-K or Form N-SAR, or portion thereof will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
- (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III  
NARRATIVE

State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR or the transition report portion thereof could not be filed within the prescribed time period.

The Company's Annual Report on Form 10-KSB for the year ended January 31, 2005 cannot be filed within the prescribed time period because the Company is experiencing delays in the collection and compilation of certain information required to be included in the Form 10-KSB. The Company's Annual Report on Form 10-KSB will be filed on or before the 15th calendar day following the prescribed due date.

PART IV  
OTHER INFORMATION

- (1) Name and telephone number of person to contact in regard to this notification: V. RANDY WHITE, CHIEF EXECUTIVE OFFICER AT (212) 297-0808

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed?  
If the answer is no, identify report(s)

[X] Yes [ ] No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

[X] Yes [ ] No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reason why a reasonable estimate of the results cannot be made.

Xenomics, Inc.'s financial statements for the year ended January 31, 2005 to be included in Xenomics's Form 10-KSB for the year ended January 31, 2005 will reflect (i) \$545,231 of research and development expense and (ii) \$651,695 of general and administrative expense. In addition, Xenomics currently is in the process of compiling information related to purchased in-process research and development expense incurred during the year ended January 31, 2005 which we expect to be approximately \$2,145,000.

Xenomics, Inc.'s financial statements for the year ended January 31, 2005 to be included in Xenomics' Form 10-KSB for the year ended January 31, 2005 will reflect consolidated loss from operation of \$3,336,018 as compared to a loss of \$521 for the twelve months ended January 31, 2004.

XENOMICS, INC.

-----  
(Name of Registrant as specified in Charter)

has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Date: MAY 2, 2005  
-----

By: /S/ V. RANDY WHITE  
-----

V. Randy White  
Chief Executive Officer